This study is single, centre trial to study the safety and efficacy of Bone marrow derived autologous MNCS(100 million per dose)trial to be conducted for 36 months in stroke patients , the primary outcome measure will be the improvement in muscle power of Body and face

This study is single centre trial to study the safety and efficacy of Bone marrow derived autologous MNCS(100 million per dose)trial to be conducted for 36 months in stroke patients , the primary outcome measure will be the improvement in muscle power of Body and face

Inclusion Criteria:

• Patient should suffer from stroke due to cerebral infarct or Haemorrhage or accelerated hypertension.
• willingness to undergo bone marrow derived autologous cell therapy.
• patient those provide fully Informed consent form for the study.
• Ability and willingness to regular visit to hospital and follow up during the protocol Procedure.

Exclusion Criteria:

• Patients with pre - existing or Current systemic disease such as lung , liver ( exception; History of uncomplicated Hepatitis A),gastrointestinal, Cardiac , Immunodeficiency,(including HIV) Or laboratory Investigation that could cause a neurological defect.History of Life threating Allergic or immune- mediated reaction.
• Alcohol and drug abuse / dependence.
• Severe skin infection.
• Haemodynamically unstable.
• subject with primary and secondary diabetes , Insulin depenence,